Placebo Gel
DrugPlacebo gel consist of drug without the active component.
Other names: Placebo group
NCT Number: NCT02274090
This study evaluates the efficacy of 1% Metformin gel in treatment of moderate and severe periodontitis subject.
Looking for future studies?
Notify Me30 year–50 year
All sexes
Interventional
Phase 2 / Phase 3
Metformin (MF) has stimulating effect of osteoblastic lineages. In the present study seventy subjects were categorized into two treatment groups: Scaling and root planing (SRP) plus 1% MF and SRP plus placebo. Clinical parameters were recorded at baseline, 3, 6 and 9 months; they included plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD), and clinical attachment level (CAL). Radiologic assessment of intra bony defect (IBD) and percentage defect depth reduction (DDR%) was done at baseline, 6 months and 9 months interval using computer-aided software. PD, CAL and defect depth reduction was evaluated in initial pocket depth of ≥5mm and ≥7mm subgroup within placebo and MF group.
Mean probing depth reduction and mean clinical attachment level gain was found to greater in MF group than placebo group at all visits. Significantly greater mean percentage of defect depth reduction was found in MF group than the placebo sites in both ≥5mm and ≥7mm of initial periodontal pocket depth. In MF group improvement in clinical parameter were similar in both the sites, with slightly better improvement in clinical parameters in initial pocket depth ≥7mm with respect to CAL, IBD and DDR% while PD was significantly reduced in initial pocket depth of ≥7mm.
There was greater decrease in mSBI and PD and more CAL gain with significant IBD depth reduction at the sites treated with SRP plus locally delivered MF in chronic periodontitis subjects with intrabony defects as compared to placebo and effect of MF was similar in initial moderate periodontal pockets and deep pocket depths.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Placebo gel consist of drug without the active component.
Other names: Placebo group
Metformin gel consist of active component.
Other names: 1% Metformin group
Time frame: at 6 months and 9 months
Time frame: at 3 , 6 and 9 months
Time frame: at 3 , 6 and 9 months
Time frame: at 3 , 6 and 9 months
Time frame: at 3 , 6 and 9 months
Government Dental College and Research Institute, Bangalore
Other
Local Drug Delivery of 1% Metformin Gel in Moderate and Severe Periodontitis Subjects: a Randomized Controlled Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731412
Body Weight, Mouth Diseases
Târgu Mureş, Romania
View Trial DetailsNCT06366295
Mouth Diseases, Periodontal Diseases
Warsaw, Masovian Voivodeship, Poland
View Trial DetailsNCT07721337
Mouth Diseases, Periodontal Diseases
Cairo, Egypt
View Trial DetailsNCT07488403
Gingival Diseases, Gingivitis
Antalya, KONYAALTI, Turkey (Türkiye)
View Trial Details